The efficacy of VYVANSE in the treatment of BED was demonstrated in two 12-week randomized, double-blind, multi-center, parallel-group, placebo-controlled, dose-optimization studies (Study 11 and Study 12) in adults aged 18-55 years (Study 11: N=374, Study 12: N=350) with moderate to severe BED
Peptide Information ARA-290 Structure Source PubChem ARA-290 Research ARA-290 is a novel peptide derived from erythropoietin (EPO) that has emerged as a promising therapeutic candidate across multiple disease areas
At Pure Medical Spa , we support Chicago patients with personalized GLP-1 programs that focus on results and well-being
Copyright information 2021 The Author(s) About this chapter Cite this chapter Shetty, P.N., Chauhan, J.S., Patil, M., Aggarwal, N., Rao, D